Term Loans - Additional Information (Details) - USD ($)			3 Months Ended
Term Loans - Additional Information (Details) - USD ($)	Aug. 07, 2025	Nov. 13, 2023	Mar. 31, 2026	Mar. 31, 2025	Dec. 31, 2025
Debt Instrument [Line Items]
Success fee liability at fair value			$ 1,582,000		$ 1,552,000
2025 Trinity Term Loans
Debt Instrument [Line Items]
Fair value of loan at issuance			48,961,000		$ 50,106,000
2025 Trinity Term Loans \| Trinity Lenders \| General and Administrative Expense
Debt Instrument [Line Items]
Debt issuance costs incurred			1,100,000
Trinity Term Loans
Debt Instrument [Line Items]
Interest expense related to term loan			$ 1,400,000	$ 1,300,000
2025 Trinity Term Loan Agreement
Debt Instrument [Line Items]
Percentage of calculated discounted cash flows of discount rate			13.86%
Percentage of remeasured calculated discounted cash flows of discount rate			15.61%
2025 Trinity Term Loan Agreement \| 2025 Trinity Term Loans \| Trinity Lenders
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 50,000,000
Interest rate terms description	The interest rate applicable to the 2025 Trinity Term Loans is the greater of (a) the WSJ Prime Rate plus 4.00% or (b) 11.50% per annum. The 2025 Trinity Term Loans are interest only from the Trinity Refinance Date through 48 months from the Trinity Refinance Date, which may be extended to 60 months from the Trinity Refinance Date upon the satisfaction of certain milestones set forth in the 2025 Trinity Term Loan Agreement, after which the Company is required to pay equal monthly installments of principal through August 1, 2030 (the “New Maturity Date”).
Interest rate period	48 months
Interest rate extension period	60 months
Debt outstanding			$ 50,000,000
Debt instrument, maturity date	Aug. 01, 2030
Commitment fee	$ 100,000
Current borrowing capacity	$ 50,000,000
Percentage of interest rate	11.50%
Debt instrument, basis spread on variable rate	4.00%
Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration]	us-gaap:PrimeRateMember
Commitment fee percentage	1.00%
End of term payment percentage	5.00%
Percentage of annual default interest rate	5.00%
2025 Trinity Term Loan Agreement \| 2025 Trinity Term Loans \| Trinity Lenders \| Trinity Refinance Date Until March 31, 2028
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 25,000,000
Debt instrument, maturity end date	Mar. 31, 2028
2025 Trinity Term Loan Agreement \| 2025 Trinity Term Loans \| Trinity Lenders \| Through March 31,2029
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 25,000,000
Debt instrument, maturity end date	Mar. 31, 2029
2025 Trinity Term Loan Agreement \| 2025 Trinity Term Loans \| Trinity Lenders \| Trinity Refinance Date through August 2026
Debt Instrument [Line Items]
Percentage of prepayment premium	3.00%
2025 Trinity Term Loan Agreement \| 2025 Trinity Term Loans \| Trinity Lenders \| August, 2026 through August, 2027
Debt Instrument [Line Items]
Percentage of prepayment premium	2.00%
2025 Trinity Term Loan Agreement \| 2025 Trinity Term Loans \| Trinity Lenders \| August, 2027 through, but Excluding, the Maturity Date
Debt Instrument [Line Items]
Percentage of prepayment premium	1.00%
2025 Trinity Term Loan Agreement \| 2025 Trinity Term Loans \| Trinity Lenders \| General and Administrative Expense
Debt Instrument [Line Items]
Debt issuance costs incurred			1,000,000
2025 Trinity Term Loan Agreement \| 2025 Trinity Term Loans \| Third Parties \| General and Administrative Expense
Debt Instrument [Line Items]
Debt issuance costs incurred			$ 100,000
Success Fee Agreement
Debt Instrument [Line Items]
Percentage of calculated discounted cash flows of discount rate			13.86%
Percentage of remeasured calculated discounted cash flows of discount rate			15.61%
Success Fee Agreement \| 2025 Trinity Term Loans \| Trinity Lenders
Debt Instrument [Line Items]
Success fee liability at fair value			$ 200,000
Fair value of loan at issuance			49,800,000
Percentage of principal amount of terms regarding fee	5.00%
Debt instrument, fee amount	$ 500,000
Success Fee Agreement \| Trinity Term Loans \| Trinity Lenders
Debt Instrument [Line Items]
Fair value of loan at issuance			49,000,000
Success fees			$ 1,600,000
2023 Trinity Term Loan Agreement \| 2023 Trinity Term Loans \| Trinity Lenders
Debt Instrument [Line Items]
Maximum borrowing capacity		$ 40,000,000
Interest rate terms description		The interest rate applicable to the 2023 Trinity Term Loans was the greater of (a) the Wall Street Journal (“WSJ”) Prime Rate plus 4.50% or (b) 12.75% per annum. The 2023 Trinity Term Loans were interest only from the Trinity Closing Date through 36 months from the Trinity Closing Date, which could have been extended to 48 months from the Trinity Closing Date upon the satisfaction of certain milestones set forth in the 2023 Trinity Term Loan Agreement, after which the Company was required to pay equal monthly installments of principal through November 13, 2028 (the “Maturity Date”).
Interest rate period		36 months
Interest rate extension period		48 months
Debt instrument, maturity date		Nov. 13, 2028
Percentage of interest rate		12.75%
Debt instrument, basis spread on variable rate		4.50%
Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration]		us-gaap:PrimeRateMember
Commitment fee percentage		1.00%
End of term payment		$ 600,000
2023 Trinity Term Loan Agreement \| 2023 Trinity Term Loans \| Trinity Lenders \| Closing Date through November 13, 2024
Debt Instrument [Line Items]
Percentage of prepayment premium		3.00%
2023 Trinity Term Loan Agreement \| 2023 Trinity Term Loans \| Trinity Lenders \| November 13, 2024 through November 13, 2025
Debt Instrument [Line Items]
Percentage of prepayment premium		2.00%
2023 Trinity Term Loan Agreement \| 2023 Trinity Term Loans \| Trinity Lenders \| November 13, 2025 through, but excluding, the Maturity Date
Debt Instrument [Line Items]
Percentage of prepayment premium		1.00%
2023 Success Fee Agreement \| 2023 Trinity Term Loans \| Trinity Lenders
Debt Instrument [Line Items]
Percentage of principal amount of terms regarding fee		10.00%
Expiration Period		10 years

Taysha Gene Therapies, Inc. 10-Q